Skip to content

The Value of Spleen Stiffness Measurement in Patients With PBC

The Value of Spleen Stiffness Measurement in Patients With PBC

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07319169
Enrollment
125
Registered
2026-01-06
Start date
2026-01-31
Completion date
2028-01-31
Last updated
2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Biliary Cholangitis, Spleen Stiffness

Keywords

spleen stiffness, primary biliairy cholangitis

Brief summary

Recent evidence suggests that combining liver stiffness measurement (LSM) with spleen stiffness measurement (SSM) significantly improves risk stratification in patients with PBC. In a study the addition of spleen stiffness to liver stiffness enhanced the prediction of liver decompensation, providing a more precise evaluation of portal hypertension. Furthermore, when combined with platelet count, this approach effectively identified patients with a low probability of harboring HRVs. This could allow clinicians to safely avoid unnecessary endoscopic procedures in selected patients, improving patient comfort and reducing healthcare costs. Therefore, our patients participating in this trial will undergo follow up (every 6 months) as per Standard of care. This includes a blood draw, FibroScan and Ultrasound. Together with this, 2 questionnaires will be completed (not as per SOC) and during the FibroScan, a spleen stiffness measurement will be performed.

Interventions

spleen stiffness measurement - during FibroScan

Sponsors

Universitair Ziekenhuis Brussel
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥18y * Out-patient, followed at the UZ Brussels * Diagnosis of PBC based on cholestasis, AMA positivity and/or biopsy. * Under treatment with ursodeoxycholic acid and/or bezafibrate

Exclusion criteria

* \<18y * Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.

Design outcomes

Primary

MeasureTime frameDescription
Correlation between spleen stiffness measurement and biochemical assessment of severity of PBC.from signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)
Correlation between spleen stiffness measurement and clinical signs of portal hypertension, liver related events and PH-related bleedingfrom signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)
Correlation between spleen stiffness measurement and endoscopic signs of portal hypertension, liver related events and PH-related bleedingfrom signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)
Correlation between spleen stiffness measurement and quality of life assessment of severity of PBC.from signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)
Evaluation of the evolution of liver or spleen stiffness on treatment of PBCfrom signing the ICF till end of study (could be up to 5 years, assessments are done every 6 months)liver or spleen stiffness measurement is done using FibroScan

Countries

Belgium

Contacts

Primary ContactSilke François
silke.francois@uzbrussel.be+32 2 477 60 11

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026